Takeda, CSL to end alliance as plasma-based COVID-19 drug fails key test
Bio Pharma Dive
APRIL 5, 2021
An unusual partnership to develop a standardized plasma therapy for COVID-19 didn't succeed, but could be a model for collaborations should another public health crisis arise, the drugmakers said.
Let's personalize your content